Bosch develops rapid test for COVID-19

One of the world’s first fully automated molecular diagnostic tests for medical institutions

Bosch develops rapid test for COVID-19

Bosch Healthcare Solutions, together with Randox Laboratories Ltd., has developed one of the world’s first fully automated molecular diagnostic tests.

Bosch’s new, fully automated rapid test for COVID-19 can help medical facilities such as doctors’ offices, hospitals, laboratories, and health centers make fast diagnoses.

The molecular diagnostic test runs on the Vivalytic analysis device from Bosch Healthcare Solutions.

Dr. Volkmar Denner, chairman of the board of management of Robert Bosch GmbH, said: “We want the Bosch rapid COVID-19 test to play a part in containing the coronavirus pandemic as quickly as possible.

“It will speed up the identification and isolation of infected patients.”

Faster certainty, slower spread

Developed in just six weeks, the test can detect a SARS-CoV-2 coronavirus infection in patients in under two and a half hours – measured from the time the sample is taken to the time the result arrives.

The test can be performed directly at the point of care.

With the tests currently in use, patients must usually wait one to two days for a result.

How it works

A sample is taken from the patient’s nose or throat using a swab.

Then the cartridge, which already contains all the reagents required for the test, is inserted into the Vivalytic device for analysis.

The Vivalytic analyzer is designed to be so user-friendly that even medical personnel who have not been specially trained on it can reliably perform the test.

A Bosch Vivalytic analyzer can perform up to ten tests in the space of 24 hours.

The rapid test meets the quality standards of the World Health Organization (WHO).

Bosch’s new test is one of the world’s first fully automated molecular diagnostic tests that can be used directly by all medical institutions.

What’s more, it allows a single sample to be tested not just for COVID-19 but also for nine other respiratory diseases, including influenza A and B, simultaneously.

The newly developed test will be available in Germany starting in April, with other markets in Europe and elsewhere to follow.

For further information about Bosch, select ‘more details’ below.

Have your say!

0 0

Lost Password

Please enter your username or email address. You will receive a link to create a new password via email.